ClinicalTrials.gg
Status unknownNCT02749123Updated Apr 22, 2016

Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis

An interventional study of lidocaine 5% patch and lidocaine 3.6%, menthol 1.25% in Back Pain and Arthritis, sponsored by J.A.R. Laboratories. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-22.

Sponsored by J.A.R. Laboratories · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.

Planned enrollment
115th of 262
100 · median 76
Started
2016
with 7 others
No phase
163 of 307
17 open now
Registered
139th of 307
by date

Among the 307 studies in Back Pain with a site in United States, this one is the 115th largest by planned enrollment of the 262 interventional ones that give a count, is one of 8 that started in 2016, is one of 163 with no phase, and was the 139th registered.

Back Pain

728 studies on the registry are indexed under Back Pain; 109 are open to participants now.

Browse Back Pain studies →

Open to participants now

38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Back Pain with a site in United States, or all of them as a file.
02

Study summary

A comparison of transdermal patches for efficacy, side effects and quality of life for patients with back pain and arthritis. The three arms in the trial were; prescription strength lidocaine 5%, over the counter lidocaine 3.6%, menthol 1.25% and placebo.

Read the detailed description

In this comparison of; lidocaine 5%, lidocaine/menthol 1.25% and placebo for patients with back pain and arthritis, subjects had to qualify by meeting various inclusion and exclusion criteria. Subjects signed an informed consent and were randomized in a double blinded fashion to one of the three arms. After randomization subjects completed a baseline questionnaire regarding how pain affects their lives. Then they began therapy with their blinded product. This same questionnaire was administered after the second day of therapy and after the final day on day 10. Responses at the day two and ten endpoints were compared to baseline to access the response of each arm.

03

Conditions studied

  • Back Pain
  • Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of back pain
  • Diagnosis of arthritis

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or expected pregnancy in the next three months
  • Allergic to any lidocaine, menthol and methylparaben
  • No reliable access to the internet
  • Baseline average pain intensity of 1,2,9 or 10 on a scale of 0-to 10.
  • Pain on the area of the body not conducive to patch therapy (eg fingers, toes etc)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Lidocaine5% v Lidocaine3.6%,Menthol1.25%

    Daily patch Q12 followed by Q12 of no patch

    Drug: lidocaine 5% patch · Drug: lidocaine 3.6%, menthol 1.25%

  • Placebo comparator
    Lidocaine 3.6%, menthol 1.25% v placebo

    Daily patch Q12 followed by Q12 of no patch

    Drug: lidocaine 3.6%, menthol 1.25% · Drug: Placebo

Interventions

  • 10cmx 14 cm transdermal patch sealed in its own pouch

    Also known as: Lidoderm

  • 10cmx 14 cm transdermal patch sealed in its own pouch

    Also known as: LidoPatch

  • DrugPlacebo

    patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch

06

What researchers measure

Primary outcomes

  1. Efficacy comparison of lidocaine 5% and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale

    Endpoint is a non-inferiority statistical comparison. Comparison is based off of analysis of identical questionnaires administered at baseline and day ten

    Time frame: Day ten

Secondary outcomes

  1. Quality of life comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale

    Statistical superiority sought for lidocaine 3.6%,menthol 1.25% compared to placebo. Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.

    Time frame: Day ten

  2. Efficacy comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale

    Statistical superiority sought for lidocaine 3.6%,menthol 1.25% compared to placebo. Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.

    Time frame: Day 10

  3. Side effect comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale

    Endpoint is a non-inferiority statistical comparison. Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.

    Time frame: Day 10

  4. Side effect comparison of lidocaine 5% and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale

    Endpoint is a non-inferiority statistical comparison. Comparison is based off of analysis of identical questionnaires administered at baseline and day ten.

    Time frame: Day 10

07

Study locations

1 of 1 sites recruiting
  • Advocate Good Sheppard Hospital
    Barrington, Illinois 60010, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Investigators plan to share the study results as a whole but no plans to share individual results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2016
First posted
Apr 22, 2016
Start
Apr 2016
Primary completionEst.
May 2016
CompletionEst.
May 2016
Last update
Apr 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02749123
Lead sponsor
J.A.R. Laboratories
Responsible party
Sponsor
First posted
Apr 22, 2016
Start date
Apr 2016
Primary completion
May 2016 (estimated)
Completion
May 2016 (estimated)
Last update
Apr 22, 2016

Study contacts

James J Ciullo, MBA
Contact
jay@lidopatch.com
6302512873
Eric Castro, MD
Contact
jedc269@yahoo.com
773-771-4160

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion